高危儿童白血病单倍体移植:两种平台回顾性比较
西班牙10中心回顾192例高危血液肿瘤患儿,中位年龄8.6岁,接受PT-Cy或体外TCD单倍体移植。植入率91.3%,供者<30岁和慢性GVHD为生存有利因素,移植前MRD阳性和淋巴系疾病为不利因素。两平台OS、DFS和复发无差异,复发仍是主要问题。
要点
- 供者<30岁和发生慢性GVHD与更好生存相关
- 移植前MRD阳性和淋巴系疾病与更差生存相关
- PT-Cy与体外TCD平台生存和复发无差异
核心结论
- 两种单倍体移植平台均有效,中心可依据自身熟练度选择。
- 复发仍是两种平台的主要问题,应作为未来努力方向。
研究设计与样本
- 41例接受未处理移植物联合PT-Cy预防GVHD,151例接受体外TCD的PBSC(CD34+选择、CD3+CD19+去除、TCRαβ+CD19+去除或CD45RA+去除联合CD34+选择)。
主要发现
- 植入率为91.3%。
- 供者<30岁和发生慢性GVHD是影响生存的有利因素。
- 移植前MRD阳性和淋巴系疾病是影响生存的不利因素。
- 淋巴系恶性肿瘤、供者KIR单倍型A和移植前MRD阳性增加复发概率。
- 两种平台在总生存、无病生存或复发发生率方面无差异。
临床怎么用
- 中心可根据自身对PT-Cy或体外TCD平台的熟练程度选择单倍体移植方案。
- 移植前应关注MRD状态和疾病类型以评估复发风险。
- 选择供者时可考虑供者年龄和KIR单倍型。
局限性
- 回顾性比较分析,非随机分组。
- 样本来自西班牙10个中心,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A total of 192 pediatric patients, median age 8.6 years, with high-risk hematological malignancies, underwent haploidentical stem cell transplantation (haplo-HSCT) using post-transplantation cyclophosphamide (PT-Cy), or ex vivo T cell-depleted (TCD) graft platforms, from January 1999 to December 2016 in 10 centers in Spain. Some 41 patients received an unmanipulated graft followed by PT-Cy for graft-vs-host disease (GvHD) prophylaxis. A total of 151 patients were transplanted with CD3-depleted peripheral blood stem cells (PBSCs) by either CD34+ selection, CD3+ CD19+ depletion, TCRαβ+ CD19+ depletion or CD45RA+ depletion, added to CD34+ selection for GvHD prophylaxis. The PBSCs were the only source in patients following ex vivo TCD haplo-HSCT; bone marrow was the source in 9 of 41 patients following PT-CY haplo-HSCT. Engraftment was achieved in 91.3% of cases. A donor younger than 30 years, and the development of chronic GvHD were positive factors influencing survival, whereas positive minimal residual disease (MRD) before transplant and lymphoid disease were negative factors. The probability of relapse increased with lymphoid malignancies, a donor killer-cell immunoglobulin-like receptor (KIR) haplotype A and positive MRD pretransplant. No difference was found in overall survival, disease-free survival or relapse incidence between the two platforms. Relapse is still of concern in both platforms, and it should be the focus of future efforts. In conclusion, both platforms for haplo-HSCT were effective and could be utilized depending on the comfort level of the center.
引用
- Pérez-Martínez A, Ferreras C, Pascual A, et al. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working Group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2019. PMID: 31625177. doi:10.1002/ajh.25661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。